Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Guangdong South China Vaccine, Guangzhou, China.
Vaccine. 2021 Apr 15;39(16):2280-2287. doi: 10.1016/j.vaccine.2021.03.006. Epub 2021 Mar 5.
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.
全球严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）大流行的出现突显了快速开发非侵入性疫苗的重要性，这种疫苗可以很容易地施用于人体。针对呼吸道病毒，通过鼻腔给药的疫苗具有这样的特性。在这项研究中，我们生成了一种基于 SARS-CoV-2 受体结合域（RBD）的重组亚单位疫苗。通过鼻腔接种、微针皮内注射或肌肉注射对小鼠进行免疫接种，然后比较 RBD 特异性免疫反应。结果表明，当经鼻腔给药时，该疫苗可引发强烈的全身性体液免疫反应，产生高滴度的 IgG 抗体和中和抗体，以及显著的黏膜免疫反应。此外，还分析了抗原特异性 T 细胞反应。这些结果表明，未来 SARS-CoV-2 疫苗的设计应探索非侵入性的鼻腔给药途径。
Zotero 插件
